Michael A Collier1, Matthew D Gallovic2, Eric M Bachelder1, Craig D Sykes3, Angela Kashuba3, Kristy M Ainslie4. 1. Division of Molecular Pharmaceutics, Eshelman College of Pharmacy, University of North Carolina, 4211 Marsico Hall, 125 Mason Farm Road, Chapel Hill, North Carolina, 27599, USA. 2. William G. Lowrie Department of Chemical and Biomolecular Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, 43210, USA. 3. Division of Experimental Therapeutics, Eshelman College of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, 27599, USA. 4. Division of Molecular Pharmaceutics, Eshelman College of Pharmacy, University of North Carolina, 4211 Marsico Hall, 125 Mason Farm Road, Chapel Hill, North Carolina, 27599, USA. ainsliek@email.unc.edu.
Abstract
PURPOSE: Since the adoption of highly active antiretroviral therapy, HIV disease progression has slowed across the world; however, patients are often required to take multiple medications daily of poorly bioavailable drugs via the oral route, leading to gastrointestinal irritation. Recently, long acting antiretroviral injectables that deliver drug for months at a time have moved into late phase clinical trials. Unfortunately, these solid phase crystal formulations have inherent drawbacks in potential dose dumping and a greater likelihood for burst release of drug compared to polymeric formulations. METHODS: Using electrospinning, acetalated dextran scaffolds containing the protease inhibitor saquinavir were created. Grinding techniques were then used to process these scaffolds into injectables which are termed saquinavir microconfetti. Microconfetti was analyzed for in vitro and in vivo release kinetics. RESULTS: Highly saquinavir loaded acetalated dextran electrospun fibers were able to be formed and processed into saquinavir microconfetti while other polymers such as poly lactic-co-glycolic acid and polycaprolactone were unable to do so. Saquinavir microconfetti release kinetics were able to be tuned via drug loading and polymer degradation rates. In vivo, a single subcutaneous injection of saquinavir microconfetti released drug for greater than a week with large tissue retention. CONCLUSIONS: Microconfetti is a uniquely tunable long acting injectable that would reduce the formation of adherence related HIV resistance. Our findings suggest that the injectable microconfetti delivery system could be used for long acting controlled release of saquinavir and other hydrophobic small molecule drugs.
PURPOSE: Since the adoption of highly active antiretroviral therapy, HIV disease progression has slowed across the world; however, patients are often required to take multiple medications daily of poorly bioavailable drugs via the oral route, leading to gastrointestinal irritation. Recently, long acting antiretroviral injectables that deliver drug for months at a time have moved into late phase clinical trials. Unfortunately, these solid phase crystal formulations have inherent drawbacks in potential dose dumping and a greater likelihood for burst release of drug compared to polymeric formulations. METHODS: Using electrospinning, acetalated dextran scaffolds containing the protease inhibitor saquinavir were created. Grinding techniques were then used to process these scaffolds into injectables which are termed saquinavir microconfetti. Microconfetti was analyzed for in vitro and in vivo release kinetics. RESULTS: Highly saquinavir loaded acetalated dextran electrospun fibers were able to be formed and processed into saquinavir microconfetti while other polymers such as poly lactic-co-glycolic acid and polycaprolactone were unable to do so. Saquinavir microconfetti release kinetics were able to be tuned via drug loading and polymer degradation rates. In vivo, a single subcutaneous injection of saquinavir microconfetti released drug for greater than a week with large tissue retention. CONCLUSIONS: Microconfetti is a uniquely tunable long acting injectable that would reduce the formation of adherence related HIV resistance. Our findings suggest that the injectable microconfetti delivery system could be used for long acting controlled release of saquinavir and other hydrophobic small molecule drugs.
Entities:
Keywords:
Biodegradable polymers; Drug delivery; Electrospinning; Microconfetti
Authors: N Tanji; M D Ross; K Tanji; L A Bruggeman; G S Markowitz; P E Klotman; V D D'Agati Journal: Histol Histopathol Date: 2006-04 Impact factor: 2.303
Authors: D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191
Authors: H W Millie Fung; Traci J T Mikasa; Julie Vergara; Sandra J Sivananthan; Jeffrey A Guderian; Malcolm S Duthie; Thomas S Vedvick; Christopher B Fox Journal: J Nanobiotechnology Date: 2013-12-21 Impact factor: 10.435
Authors: Kathryn M Moore; Cole J Batty; Rebeca T Stiepel; Christopher J Genito; Eric M Bachelder; Kristy M Ainslie Journal: ACS Appl Mater Interfaces Date: 2020-08-24 Impact factor: 9.229